Promising candidates for molecular targeted therapy in ameloblastoma include vemurafenib and dabrafenib to target mutated BRAF, trametinib for MEK mutations, and ponatinib and regorafenib for FGFR2 mutations; vemurafenib and dabrafenib for BRAF and trametinib for MEK were three molecular targeted therapies for BRAF V600E mutations sanctioned by the US Food and Drug Administration (30). This evidence concerns the gene MAP2K7 and ameloblastoma.